Pierre Fabre Pharmaceuticals (Usa)

Pierre Fabre Pharmaceuticals (Usa) company information, Employees & Contact Information

The mission of Pierre Fabre Pharmaceuticals (PFP) is to deliver breakthrough therapies in oncology and rare diseases to patient populations with high unmet needs and limited treatment options. Our belief is that every time we care for a single person, we make the whole world better. PFP is the US pharmaceutical subsidiary of Pierre Fabre Laboratories, a foundation-owned company with seven decades of impact. Pierre Fabre Laboratories is a global healthcare company, established in 43 countries, with 10,000 employees, and with products distributed in 120 territories across the globe. The Pierre Fabre Laboratories foundation ownership enhances the ability of the company to create long-term value for patients. Partnerships and acquisitions drive its innovative precision treatment pipeline and are enabled by the unique corporate structure. Building on the legacy of Pierre Fabre Laboratories, innovation is the life blood of PFP and patient experience drives everything the company does. PFP aspires to design and develop therapeutic solutions inspired by patients and healthcare professionals; draw on science and nature as perpetual sources of inspiration; develop long-term partnerships with researchers and innovators worldwide; and place pharmaceutical ethics and climate transition at the heart of our action. Pierre Fabre Pharmaceuticals has therapies in development for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), NRAS-mutant melanoma, non-small cell lung cancer with mutation or amplification of MET, and X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Pierre Fabre Pharmaceuticals is headquartered in Parsippany, NJ.

Company Details

Employees
93
Founded
-
Address
Secaucus, New Jersey
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Secaucus, New Jersey
Looking for a particular Pierre Fabre Pharmaceuticals (Usa) employee's phone or email?

Pierre Fabre Pharmaceuticals (Usa) Questions

News

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PR Newswire

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) PR Newswire

Breakthrough: FDA Fast-Tracks First-Ever Cell Therapy for Fatal Post-Transplant Cancer - Stock Titan

Breakthrough: FDA Fast-Tracks First-Ever Cell Therapy for Fatal Post-Transplant Cancer Stock Titan

Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PR Newswire

Pierre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. PR Newswire

Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan

Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission Stock Titan

FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease - OncLive

FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease OncLive

Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ - PR Newswire

Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ PR Newswire

Pierre Fabre Pharmaceuticals Inc. announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - PR Newswire

Pierre Fabre Pharmaceuticals Inc. announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease PR Newswire

Top Pierre Fabre Pharmaceuticals (Usa) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant